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Background/aim: Synthetic cannabinoids (SCs) are full agonists of both cannabinoid receptors. Conventional magnetic resonance
imaging (MRI) findings of SC users are mainly defined as diffusion restriction and T2/FLAIR hyperintensity. Diffusion tensor imaging
(DTI) studies examining SC users have shown contradictory results. The aim of this study was to define white matter (WM) changes of
SC users using DTI.
Materials and methods: The study included 22 patients with a history of using SC for 5–37 months, and 22 healthy, age and sexmatched control subjects. A total of 41 diffusion gradient directions were used in the acquisition of diffusion imaging data. Fractional
anisotropy (FA) and apparent diffusion coefficients (ADC) values were obtained. ROIs were placed on WM areas of normal appearance.
Results: In the SC users, significantly lower FA values were determined in the left temporal lobe (216.2 ± 58.9 vs. 263 ± 27.4; P =
0.002) and right hippocampus (224.5 ± 61.5 vs. 255 ± 24.3; P = 0.040). The ADC values of the hippocampus and temporal lobe were
significantly higher than those of the control group on both the left and right sides.
Conclusion: The SC use causes WM microstructural changes, especially in the hippocampus and temporal lobes. DTI is a useful tool to
reveal WM changes in SC addicts and can be used earlier than conventional MRI.
Key words: Bonzai, synthetic cannabinoids, white matter, diffusion tensor imaging

1. Introduction
Synthetic cannabinoids (SCs) are full agonists of both
cannabinoid receptors (CB 1 and CB 2). There are various
names to define SCs, such as Bonzai, Jamaika, Aroma, K2, or
Kronic. SCs are preferred to original cannabinoid products
because they are cheaper, more readily available, and more
difficult to detect in drug tests [1,2].
The harmful effects of SCs are similar to those of natural
cannabis. As SCs contain various compounds, they can
result in greater toxicity than natural cannabis. The most
frequent adverse effect to the central nervous system (CNS)
is embolic ischemic stroke, similar to that induced by natural
cannabis [3].
Conventional magnetic resonance imaging (MRI)
findings of SC users are mainly defined as diffusion restriction
and T2/FLAIR hyperintensity [4]. Diffusion tensor imaging
(DTI) is an MRI technique that is used to assess white matter
(WM) microstructure. DTI is an effective tool to assess
WM injury by means of quantitatively evaluating fractional

anisotropy of brain-water diffusion and the myelin sheath
of brain WM fiber bundles. The SC use has been known to
reduce the integrity of WM [5]. Fractional anisotropy (FA)
is a parameter of DTIthat can be defined as an index for the
amount of diffusion asymmetry within a voxel. FA indirectly
represents the WM microstructure, and axonal damage or
demyelization is associated with reduced FA values [6].
DTI studies examining SC users have shown
contradictory results. Some studies have indicated that
FA values in SC users increased [7,8], whereas others have
reported decreased FA values [9,10]. In addition, these
studies have only focused on natural cannabis use.
The aim of the current study was to define WM changes
in the CNS of SC users in comparison with normal controls
using DTI.
2. Materials and methods
The current study included a total of 22 patients with a
history of SC use for 5–37 months and 22 healthy, age
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and sex-matched control subjects. Any patients with
a diagnosis of alcoholism or any addiction other than
SC, neurological or psychiatric disorders other than SC
addiction, severe hepatic, renal or endocrine disease, and
those with a contraindication for MRI examination were
excluded from the study.
The SC users included in the study were also tested
using the Montreal cognitive assessment (MoCA) test [11]
to define cognitive functions and any possible relationship
between cognitive impairments and DTI findings.
MRI examinations were performed with a 1.5 Tesla
MRI system (Magnetom Aera, Siemens Healthcare GmbH,
Erlangen, Germany). The diffusion imaging data were
acquired from 41 diffusion gradient directions (b-value =
1000 s/mm2) and T2 and FLAIR reference images were
also obtained (repetition time = 6500 ms, echo time = 90
ms, voxel size=1 ×1 ×2 mm3). The DTI protocol involved
structural 3D-T1, T2-weighted images.
FA maps were created on a Siemens, Leonardo
workstation using the Neuro3D application, and FA values
were then measured on the FA maps. ADC values were
obtained using the same software.
FA and apparent diffusion coefficients (ADC) values
were acquired using approximately 30 mm2 regions of
interest (ROI). ROIs were placed on WM areas of normal
appearance if any WM lesions were present on T2 or FLAIR
images. All measurements were performed by the same
researcher (SA). Three ROIs were placed into the examined
location, and the mean values of 3 measurements were
recorded as the final data. Measurements were performed
from temporal lobes, the hippocampus, and the brainstem
since SCs have been known to affect the limbic system and,
in addition, previously performed DTI studies generally
chose the same locations (5). The brainstem was also
preferred in the investigation of life-threatening effects.

Measurement levels can be seen in Figure 1.Approval for
the study was granted by the Institutional Ethics Review
Board, and informed consent was obtained from each
participant.
2.1. Statistical analysis
Data obtained in the study were analyzed statistically
using SPSS statistics 21.0 (IBM Corp., Armonk, NY, USA).
Normal distribution was tested with the KolmogorovSmirnov test. Continuous parameters were stated as mean
± standard deviation (SD), and numerical variables without
normal distribution were shown as median (minimummaximum) values. Normally distributed variables were
compared between the patients and control groups with
the Student’s t-test, whereas parameters with abnormal
distribution were compared via the Mann-Whitney U test
between the 2 groups. The correlations between age, sex,
duration of usage, and FA values were evaluated with the
Pearson and Spearman correlation tests.A two-tailed value
of P < 0.05 was considered statistically significant.
3. Results
All of the participants were male, and all were currently
using SC. Both the SC users and control subjects smoked
at least one pack of cigarettes a day. The mean age of the SC
users and control group were 23.3 ± 5.6 years and 22.7±4.8
years, respectively. Median duration of SC use was 13 (5–
37) months, and median daily SC use was 4 (1–12) times
per day.
The median MoCA test result of the SC users was 27;
only 3 SC users had an abnormal test result (18,18, and 20
points, respectively, with ≤21 points defined as abnormal).
Conventional MRIs of the patients were mostly
normal. Subcentimeter WM lesions were detected in only
4 patients. The lesions were located at the temporal (3
patients) and parietal (1 patient) lobes.

Figure 1. Measurement levels. Temporal lobe (a), hippocampus (b), and brainstem (c).
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Significantly lower FA values were obtained from the
left temporal lobe (216.2 ± 58.9 vs. 263 ± 27.4; P = 0.002)
and right hippocampus (224.5 ± 61.5 vs. 255 ± 24.3; P =
0.040) in the SC group than from the healthy control group
(Figure 2). The FA values obtained from the brainstem
were similar in the SC users and the control group (435.6
± 36.5 vs. 442.1 ± 62.2) (Table 1) (Figure 3).
The ADC values acquired from the brainstem did not
differ between the SC users and the control group (703.3
± 145.2 vs. 752.7 ± 24.2). In the SC group, the ADC values
of the hippocampus and temporal lobe were significantly
higher than those of the control group for both the left and
right sides (right temporal: 824.5 ± 41.6 vs. 791.5 ± 16.4;
P = 0.002; left temporal: 838 ± 28.5 vs. 807.8 ± 38.4; P =
0.005; right hippocampus: 849.2 ± 87.8 vs. 792.6 ± 20.1; P
=0.007; left hippocampus: 859 ± 116.2 vs. 803.2 ± 25.9; P =
0.038) (Table 2). No significant correlation was determined
between the ADC and FA values and age, duration of
usage, and amount of daily use. No significant correlation
was detected between the MoCA results and FA and ADC
values. The number of patients with an abnormal MoCA
result (3 patients) was insufficient for statistical analysis to
be applied.
4. Discussion
The main aim of the current study was to define WM
changes resulting from SC use. The results showed that

SC addiction causes WM structural changes, and these
changes can be revealed with DTI.
Cannabinoids are widely used throughout the world.
The main psychoactive compound of cannabinoids is
tetrahydrocannabinol, which can activate cannabinoid
receptors in the brain. Cannabinoid receptors are mostly
located in basal ganglia, the cerebellum, and limbic cortices.
SCs are cannabinoid-like substances that are widely used
because of their cheap costs and easy availability [12]. In
Turkey, the most popular SC is Bonzai, and its chemical
compound mainly consists of JWH-081 [13].
There is limited information in the literature about
SC toxicity on the CNS, and the studies thathave been
published are generally case reports. The toxic findings
defined in the literature are related to the combination of
direct neurotoxicity and cerebral hypoxia, as in natural
cannabinoids. Therefore, MRI findings generally present
ischemic findings [14,15]. In a case report about JWH-081
toxicity, it was stated that JWH-081 might cause myelin
toxicity and leukoencephalopathy, although the report
only contained conventional MRI data [4].
It has been emphasized in the literature that myelinrelated genes, myelin basic proteins, and myelin
proteolipid proteins are altered following prolonged
exposure to cannabis [16]. Chronic SC exposure has also
been shown to cause dose-dependent downregulation of
CB1 receptors in an animal model (rodents), especially in

Figure 2. Male, 22 years old, SC addict. ADC map (a) and FA map (b) can be seen. ROI was placed on the right
hippocampus. ADC value is 893; FA value is 231 (significantly lower than the control group).
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Table 1. Significantly different FA values.
SC users

Control group P-value

Left temporal lobe

216.2 ± 58.9

263 ± 27.4

0.002

Right hippocampus

224.5 ± 61.5

255 ± 24.3

0.040

Table 2. Significantly different ADC values.
SC users

Control group P-value

Right temporal lobe

824.5 ± 41.6

791.5 ± 16.4

0.02

Left temporal lobe

838 ± 28.5

807.8 ± 38.4

0.005

Right hippocampus

849.2 ± 87.8

792.6 ± 20.1

0.007

Left hippocampus

859 ± 116.2

803.2 ± 25,9

0.038

the hypothalamus and hippocampus. This downregulation
might cause apoptosis of oligodendrocytes, the myelinating
cells in the CNS, and thereby deplete myelinization
[17,18]. Consistent with this information, the current
study results demonstrated that the WM of SC users is
changed, especially in the hippocampus and temporal
lobe since the FA values obtained from these areas were
lower than those of the control group. In a similar study
[5], it was shown that SC use decreases FA values obtained

from the left temporal lobe, similar to the current study
results. However, unlike the current study’s results, the
previous study found that SC use had an effect on the left
hippocampus. This difference could be the result of the
duration of SC use. In the abovementioned study [5], all of
the participants had been using SC for 30 ± 14.4 months
(mean value); our population had a median duration of
use of 15 months. Therefore, there is a need for further
prospective studies to be able to clarify the order and
process of influence on specific CNS regions. It is also
highly possible that both sides of the brain can be similarly
affectedwhen the above-mentioned pathogenesis [17,18]
is considered.
The results of the current study showed that FA values
obtained from the left temporal lobes of SC users were
significantly lower than those of the healthy control group.
These findings are consistent with the literature. Recently
performed studies have similarly stated that FA values are
reduced in the temporal lobes of cannabis users [19,20]
and in the left temporal lobe of SC users [5].
No significant FA and ADC value changes in the
brainstem were determined between SC users and the
control group, and these results were consistent with the
literature. It has been stated in previous studies that CB1
receptors are expressed at a low level in the brainstem [21],
so the effect of SC on the brainstem is weak.
The ADC values were also significantly higher in both
temporal lobes and the hippocampus of SC users in the

Figure 3. Male, 32 years old, control group. ADC map (a) and FA map (b) can be seen. ROI is placed on the brainstem.
ADC value is 741; FA value is 440 (similar to the control group).
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current study. The ADC values are also related with WM
degeneration, and this was similar to the FA values. It
has been stated that in normal aging or in degenerative
processes, ADC generally increases and FA decreases
[22,23]. The current study results of FA and ADC are both
consistent with the literature and support the effectiveness
of DTI in the detection of degenerative WM changes in
SC users.
No significant correlation was determined between
FA values and duration of use and amount of daily use,
contrary to expectations. To the best of our knowledge,
there is no study in the literature that has examined these
relationships. One possible explanation of these results
could be that downregulation of CB1 receptors occurs
earlier than after 5 months of SC use and is not dosedependent. However, it is also possible that the current
study population was not large enough to detect such a
correlation. Further prospective studies are needed to
clarify these possible relationships.
Some limitations of the study must be emphasized.
The sample size was relatively small as it is difficult to
find patients addicted to only SC and who are also willing
to participate in a study of this kind. The participants in
this study were using Bonzai, a popular SC in Turkey,
the content of which is known to be mainly JWH-018.
However, it was impossible to detect the exact content and
ratio of contents of the Bonzai used by the participants.
The study population comprised of males only, so the
results cannot be generalized to the female population.

Multiple addictions and psychiatric problems, together
with addiction, are also common problems. Addicts using
SC only were selected from their psychiatric reports and
statements. However, it was not possible to create a fully
homogenous study group. Since all of the measurements
were only performed by the same researcher one time, we
cannot offer inter/intraobserver variability data.
In conclusion, SC use causes WM microstructural
changes, especially in the hippocampus and temporal
lobes. These changes can be detected via FA and ADC
values using DTI. Therefore, DTI is a more useful tool than
conventional MRI in the early detection ofWM changes in
SC addicts.
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